BEYOND CD19 AND SOLID TUMORS?
No hard 'cell': CAR drives $134M series B for Juno as immunotherapy gains ground
By Randy Osborne
Wednesday, August 6, 2014
Juno Therapeutics Inc.'s origins in three of the country's top oncology centers apparently has done plenty to help financing options for the Seattle-based firm, which added $134 million in series B cash to boost its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline. In less than 12 months, the Seattle-based company has raised more than $300 million.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.